Global Statistics Representing Immunoassay Market Scenario
Rising prevelance of infectious and chronic devices, increasing elderly population and development of novel assays in various autoimmune diseases such as oncology and cardiology are significantly contributing to the growth of the market. Moreover, increasing application in diagnosing drug monitoring tests, toxicology testing, infectious diseases and detection of cancer biomarkers are also progressing the growth. Furthermore, increasing demand for non-invasive diagnostics techniques, high demand of reagents, analytical techniques and sensitive assays and introduction of novel biomarkers are strenthening the position of immunoassay market. As per WHO, chronic disease including heart disease, stroke, cancer, diabetes and chronic lung disease are responsible for almost 70% of all deaths worldwide. 82% of the 16Mn people died prematurely or before reaching 70 in middle and low income countries. Immunoassays offers a wide array of applications in diagnosis of disease with high senstivity and specificity as compared to other tests.
New products are being launched to meet the demand of consumers by market players. For instance, in 2017, Qiagen launched QFT-Plus, which detects latent tuberculosis infection. In the same year, Meridian Life science introduced TRUBlock Ultra. This is an active immunoassay interference blocker produced by HAMA, rheumatoid factor (RH), and heterophillic antibodies (HA).
Global immunoassay market accounted for over USD 20.5 billion in 2017 and is expected to grow at a CAGR of 8.5% during the forecast period, 2019–2026.
Global immunoassay market is segmented by product & service, platform, technology, specimen, application and end user.
By product & service, the market is segmented into reagents and kits, analyzers, and software & services. The reagents and kits segment is expected to grow at the fastest CAGR. The growth can be attributed to repeated purchase of kits and reagents in combination with increasing number of immunoassay are being performed.
Based on platform, the global immunoassay market is segmented into chemiluminescence immunoassays (CLIAs), colorimetric immunoassays (CIs), fluorescence immunoassays (FIAs), radioimmunoassays (RIAs), and other platforms. chemiluminescence immunoassays is expected to hold the largest share due to low cost of the test and high sensitivity of results.
By technology, the immunoassays market is segmented globally into enzyme-linked immunosorbent assays (ELISA), rapid tests, western blotting, enzyme-linked immunospot (ELISPOT), immuno-PCR, and other technologies. The ELISA segment is expected to generate the highest revenue in the forecast period as it is the most preferred immunoassay tests for the diagnosis of cancer, infectious diseases, and therapeutic drug level monitoring.
Based on specimen type, the market is segmented into blood, urine, saliva and other specimens. Blood samples is expected to register the highest register. This can be attributed to high prevalence of chronic disease.
By application, the global immunoassays market is divided into bone and mineral disorders, infectious diseases endocrinology, oncology, hematology, cardiology, and toxicology, blood screening, neonatal screening, autoimmune disorders and other applications. The infectious diseases segment in expected to witness the highest CAGR in the assessment period as there is high in number of infectious disease and increasing product approvals.
End user segment is classified into blood banks, hospitals, clinical laboratories, research and academic laboratories, pharmaceutical and biotechnology companies and contract research organizations (CROs), and other end users. The hospitals segment can account for the largest share as diagnostic tests in hospitals are easily accessible, time saving and provide smooth process.
Geographically, the global immunoassay market is segmented into four regions: North America, Europe, Asia Pacific, and Latin America and the Middle East & Africa (LAMEA).
North America is likely to dominate the immunoassay market due to increasing application of immunoassay techniques in cancer research, increasing adoption of low cost and compact immunoassay instruments and demand of quality of infrastructure for laboratory and clinical research. As per American Cancer Society, around 609,640 Americans are expected to die of cancer in 2018. Early screening can help in the prevention and detection of these life threatening disease.
Europe is likely to emerge as the second largest immunoassay market globally. This can be attributed to increasing cancer disease burden and strong government policies to reduce the number of chronic disease. Cancer is the second leading cause of mortality in EU after cardiovascular diseases, around than 1.4 million deaths estimated in 2018.
Asia pacific immunoassay market is expected to witness significant growth on account of increasing development and production of vaccines & drugs, growing medical treatment for infectious and chronic diseases, huge number of investment opportunities for market player and increasing number of diagnostics laboratories. In 2017, there were 11,923 combined new cases of leukemia, lymphoma and myeloma in Australia.
LAMEA is expected to witness steady growth as government health budgets in Latin America are small compared to developed economies. In addition, various cancer-awareness programmers exist but understanding of cancer risks is still inadequate. As per American Cancer Society, around 1.1 million new cancer cases and 600,000 cancer deaths are estimated to occur annually in Latin America and the Caribbean.
Some of the key players in the global immunoassay market are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd, Ortho Clinical Diagnostic, Danaher Corporation, Siemens Healthineers, DiaSorin S.p.A., Sysmex Corporation and bioMérieux SA.
Immunoassay Market Segmentation
By Product & Service
By End User
Why Buy This Report?